Baird Financial Group
MYGN icon

Baird Financial Group’s Myriad Genetics MYGN Stock Holding History

Baird Financial Group’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-38,338
Closed -$173K – 1963
2026
Q1 		$173K Buy
38,338
+16,536
+76% +$86.2K ﹤0.01% 1792
2025
Q4 		$134K Sell
21,802
-2,054
-9% -$14.9K ﹤0.01% 1761
2025
Q3 		$172K Sell
23,856
-5,203
-18% -$30.9K ﹤0.01% 1744
2025
Q2 		$154K Buy
29,059
+17,186
+145% +$102K ﹤0.01% 1722
2025
Q1 		$105K Buy
+11,873
New +$143K ﹤0.01% 1717
2022
Q3 		– Sell
-15,662
Closed -$285K – 1791
2022
Q2 		$285K Buy
15,662
+394
+3% +$8.18K ﹤0.01% 1575
2022
Q1 		$384K Buy
15,268
+957
+7% +$24.5K ﹤0.01% 1522
2021
Q4 		$395K Sell
14,311
-30
-0.2% -$869 ﹤0.01% 1570
2021
Q3 		$463K Buy
+14,341
New +$476K ﹤0.01% 1494
2016
Q4 		– Sell
-26,936
Closed -$554K – 1233
2016
Q3 		$554K Sell
26,936
-28,757
-52% -$729K 0.01% 910
2016
Q2 		$1.7M Sell
55,693
-33,305
-37% -$1.16M 0.02% 594
2016
Q1 		$3.33M Buy
88,998
+1,405
+2% +$52.9K 0.03% 437
2015
Q4 		$3.78M Sell
87,593
-19
-0% -$803 0.04% 398
2015
Q3 		$3.28M Sell
87,612
-2,635
-3% -$93.5K 0.03% 411
2015
Q2 		$3.07M Buy
+90,247
New +$3.07M 0.03% 448

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Baird Financial Group's MYGN Position: Q2 2026 in Review

Baird Financial Group sold out of Myriad Genetics (MYGN) in Q2 2026, closing a stake of 38,338 shares — an estimated $173K sold.

Baird Financial Group first reported a position in MYGN in Q2 2015 and held it in 15 quarters. The position peaked at $3.78M in Q4 2015. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Baird Financial Group reported no remaining Myriad Genetics position as of Q2 2026 after selling out during the quarter.
  • Baird Financial Group sold 38,338 Myriad Genetics shares in Q2 2026, an estimated $173K.
  • Baird Financial Group first reported a position in Myriad Genetics in Q2 2015 and held it in 15 quarters.
  • Baird Financial Group's Myriad Genetics position peaked at $3.78M in Q4 2015.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Baird Financial Group's 13F filing for Q2 2026, filed 12 Aug 2026.